1. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
by Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, Bruno C. Medeiros, Martha Arellano, Samer K. Khaled, Mrinal Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti Patel, Lori Maness-Harris, Robert Stuart, Elie Traer, Kasra Karamlou, Abdulraheem Yacoub, Richard Ghalie, Ruben Giorgino, and Ehab Atallah
BloodAdv
Volume 3(4):
February 26, 2019
© 2019 by The American Society of Hematology

2. Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518
© 2019 by The American Society of Hematology

3. Landscape of high-confidence somatic mutations detected in pretreatment BM samples.
Landscape of high-confidence somatic mutations detected in pretreatment BM samples. (A) Number of mutations in each patient by cytogenetic risk group and type of AML. (B) Frequency of each type of mutation by patient. Each column represents 1 patient and each row represents 1 specific mutation.
Guillermo Garcia-Manero et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Outcomes of patients treated with pracinostat plus azacitidine.
Outcomes of patients treated with pracinostat plus azacitidine. (A) OS for the whole cohort. (B) PFS for the whole population. (C) OS stratified by response. The plot shows how the effect of analyzing CR (as a baseline covariate) produces artificial difference; the difference between the overall curve and the curve obtained by censoring at time of CR gives a more realistic view. (D) OS stratified by cytogenetic risk group.
Guillermo Garcia-Manero et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

5. Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status.
Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status. (A) OS stratified by age. (B) OS stratified by AML subtype. (C) OS stratified by ECOG status.
Guillermo Garcia-Manero et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

6. Representative cases of longitudinal sequencing analyses.
Representative cases of longitudinal sequencing analyses. Each panel shows data for 1 patient. (A) Prolonged exposure to pracinostat plus azacitidine continued to lower mutants’ VAF. (B) Reexpansion of the original mutations on relapse after achieving CR. (C) Acquisition of a new mutation (RAD21) at the time of relapse with increase of original mutants' VAF at the time of cycle 6 before frank relapse.
Guillermo Garcia-Manero et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology